Archemix Inks Deals with Dicerna, Miragen to Apply Aptamer Tech to Drug Candidates

Under the deals, Dicerna and Miragen will have the option to acquire the exclusive rights to drug candidates developed through the alliances.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.